1
|
Song DSS, Leong SW, Ng KW, Abas F, Shaari K, Leong CO, Chung FFL, Mai CW, Hii LW, Tan PJ, Patel V. Novel 2-Benzoyl-6-(2,3-Dimethoxybenzylidene)-Cyclohexenol Confers Selectivity toward Human MLH1 Defective Cancer Cells through Synthetic Lethality. SLAS DISCOVERY : ADVANCING LIFE SCIENCES R & D 2019; 24:548-562. [PMID: 30897027 DOI: 10.1177/2472555219831405] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
DNA mismatch repair (MMR) deficiency has been associated with a higher risk of developing colorectal, endometrial, and ovarian cancer, and confers resistance in conventional chemotherapy. In addition to the lack of treatment options that work efficaciously on these MMR-deficient cancer patients, there is a great need to discover new drug leads for this purpose. In this study, we screened through a library of commercial and semisynthetic natural compounds to identify potential synthetic lethal drugs that may selectively target MLH1 mutants using MLH1 isogenic colorectal cancer cell lines and various cancer cell lines with known MLH1 status. We identified a novel diarylpentanoid analogue, 2-benzoyl-6-(2,3-dimethoxybenzylidene)-cyclohexenol, coded as AS13, that demonstrated selective toxicity toward MLH1-deficient cancer cells. Subsequent analysis suggested AS13 induced elevated levels of oxidative stress, resulting in DNA damage where only the proficient MLH1 cells were able to be repaired and hence escaping cellular death. While AS13 is modest in potency and selectivity, this discovery has the potential to lead to further drug development that may offer better treatment options for cancer patients with MLH1 deficiency.
Collapse
Affiliation(s)
| | - Sze Wei Leong
- 2 Laboratory of Natural Products, Institute of Bioscience, Universiti Putra Malaysia, Selangor, Malaysia
| | - Kwok Wen Ng
- 1 Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia
| | - Faridah Abas
- 2 Laboratory of Natural Products, Institute of Bioscience, Universiti Putra Malaysia, Selangor, Malaysia
- 3 Department of Food Science, Faculty of Food Science and Technology, Universiti Putra Malaysia, Selangor, Malaysia
| | - Khozirah Shaari
- 2 Laboratory of Natural Products, Institute of Bioscience, Universiti Putra Malaysia, Selangor, Malaysia
- 4 Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Selangor, Malaysia
| | - Chee Onn Leong
- 5 Center for Cancer and Stem Cell Research, International Medical University, Bukit Jalil, Malaysia
| | - Felicia Fei-Lei Chung
- 5 Center for Cancer and Stem Cell Research, International Medical University, Bukit Jalil, Malaysia
| | - Chun Wai Mai
- 5 Center for Cancer and Stem Cell Research, International Medical University, Bukit Jalil, Malaysia
- 6 School of Pharmacy, International Medical University, Bukit Jalil, Malaysia
| | - Ling Wei Hii
- 5 Center for Cancer and Stem Cell Research, International Medical University, Bukit Jalil, Malaysia
| | - Pei Jean Tan
- 1 Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia
| | - Vyomesh Patel
- 1 Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia
| |
Collapse
|
2
|
Hewish M, Martin SA, Elliott R, Cunningham D, Lord CJ, Ashworth A. Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress. Br J Cancer 2013; 108:983-92. [PMID: 23361057 PMCID: PMC3590674 DOI: 10.1038/bjc.2013.3] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2012] [Revised: 11/16/2012] [Accepted: 12/16/2012] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND DNA mismatch repair deficiency is present in a significant proportion of a number of solid tumours and is associated with distinct clinical behaviour. METHODS To identify the therapeutic agents that might show selectivity for mismatch repair-deficient tumour cells, we screened a pair of isogenic MLH1-deficient and MLH1-proficient tumour cell lines with a library of clinically used drugs. To test the generality of hits in the screen, selective agents were retested in cells deficient in the MSH2 mismatch repair gene. RESULTS We identified cytarabine and other related cytosine-based nucleoside analogues as being selectively toxic to MLH1 and MSH2-deficient tumour cells. The selective cytotoxicity we observed was likely caused by increased levels of cellular oxidative stress, as it could be abrogated by antioxidants. CONCLUSION We propose that cytarabine-based chemotherapy regimens may represent a tumour-selective treatment strategy for mismatch repair-deficient cancers.
Collapse
Affiliation(s)
- M Hewish
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK
- CRUK Gene Function Laboratory, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
- Department of Medicine, Royal Marsden Hospital NHS Trust, London and Surrey, UK
| | - S A Martin
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK
- CRUK Gene Function Laboratory, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
| | - R Elliott
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK
| | - D Cunningham
- Department of Medicine, Royal Marsden Hospital NHS Trust, London and Surrey, UK
| | - C J Lord
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK
| | - A Ashworth
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK
- CRUK Gene Function Laboratory, The Institute of Cancer Research, Fulham Road, London SW3 6JB, UK
| |
Collapse
|
3
|
Karakas B, Weeraratna AT, Abukhdeir AM, Konishi H, Gustin JP, Vitolo MI, Bachman KE, Park BH. P21 gene knock down does not identify genetic effectors seen with gene knock out. Cancer Biol Ther 2009; 6:1025-30. [PMID: 17611398 PMCID: PMC2667557 DOI: 10.4161/cbt.6.7.4202] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
RNA interference (RNAi) has become a popular tool for analyzing gene function in cancer research. The feasibility of using RNAi in cellular and animal models as an alternative to conventional gene knock out approaches has been demonstrated. Although these studies show that RNAi can recapitulate phenotypes seen in knock out animals and their derived cell lines, a systematic study rigorously comparing downstream effector genes between RNAi and gene knock out has not been performed. Here we present data contrasting the phenotypic and genotypic changes that occur with either stable knock down via RNAi of the cyclin dependent kinase inhibitor p21 versus its somatic cell knock out counterpart in the human mammary epithelial cell line MCF-10A. Our results demonstrate that p21 knock down clones display a growth proliferative response upon exposure to Transforming Growth Factor-Beta Type 1 (TGFbeta) similar to p21 knock out clones. However, gene expression profiles were significantly different in p21 knock down cells versus p21 knock out clones. Importantly p21 knock down clones did not display increased gene expression of interleukin-1alpha (IL-1alpha), a critical effector of this growth response previously validated in p21 knock out cells. We conclude that gene knock out can yield additional vital information that may be missed with gene knock down strategies.
Collapse
Affiliation(s)
- Bedri Karakas
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; The Johns Hopkins University School of Medicine; Baltimore, Maryland USA
| | | | - Abde M. Abukhdeir
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; The Johns Hopkins University School of Medicine; Baltimore, Maryland USA
| | - Hiroyuki Konishi
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; The Johns Hopkins University School of Medicine; Baltimore, Maryland USA
| | - John P. Gustin
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; The Johns Hopkins University School of Medicine; Baltimore, Maryland USA
| | - Michele I. Vitolo
- The Marlene and Stewart Greenebaum Cancer Center; University of Maryland School of Medicine; Baltimore, Maryland USA
| | - Kurtis E. Bachman
- The Marlene and Stewart Greenebaum Cancer Center; University of Maryland School of Medicine; Baltimore, Maryland USA
| | - Ben Ho Park
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; The Johns Hopkins University School of Medicine; Baltimore, Maryland USA
- Correspondence to: Ben Ho Park; Department of Oncology; 1650 Orleans Street; Room 1M42; Baltimore, Maryland 21231 USA; Tel.: 410.502.7399; Fax: 410.614.8397;
| |
Collapse
|
4
|
Konishi H, Karakas B, Abukhdeir AM, Lauring J, Gustin JP, Garay JP, Konishi Y, Gallmeier E, Bachman KE, Park BH. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Res 2007; 67:8460-7. [PMID: 17875684 DOI: 10.1158/0008-5472.can-07-0108] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The oncogenic function of mutant ras in mammalian cells has been extensively investigated using multiple human and animal models. These systems include overexpression of exogenous mutant ras transgenes, conditionally expressed knock-in mouse models, and somatic cell knockout of mutant and wild-type ras genes in human cancer cell lines. However, phenotypic discrepancies between knock-in mice and transgenic mutant ras overexpression prompted us to evaluate the consequences of targeted knock-in of an oncogenic K-ras mutation in the nontumorigenic human breast epithelial cell line MCF-10A and hTERT-immortalized human mammary epithelial cells. Our results show several significant differences between mutant K-ras knock-in cells versus their transgene counterparts, including limited phosphorylation of the downstream molecules extracellular signal-regulated kinase and AKT, minor proliferative capacity in the absence of an exogenous growth factor, and the inability to form colonies in semisolid medium. Analysis of 16 cancer cell lines carrying mutant K-ras genes indicated that 50% of cancer cells harbor nonoverexpressed heterozygous K-ras mutations similar to the expression seen in our knock-in cell lines. Thus, this system serves as a new model for elucidating the oncogenic contribution of mutant K-ras as expressed in a large fraction of human cancer cells.
Collapse
Affiliation(s)
- Hiroyuki Konishi
- The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|